Navigation Links
Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference
Date:3/14/2011

LAS VEGAS, March 14, 2011 /PRNewswire/ -- Researchers presented data demonstrating increased specificity of Positron Emission Mammography (PEM) when compared to  MRI for the detection of breast cancer at the National Consortium of Breast Centers' 21st Annual National Interdisciplinary Breast Center Conference held March 12 – 16, 2011 in Las Vegas, Nevada.  The poster presentation, titled Pre-Surgical Detection of Malignancies in the Contralateral Breast Using Positron Emission Mammography: Comparisons with Magnetic Resonance Imaging, reveals the results of a 208 patient, single-site, IRB-approved, prospective study.

Women with newly diagnosed breast cancer have a 3-5% incidence of synchronous contralateral cancer (cancer in the opposite breast).  Because of this increased risk, accurate evaluation of the contralateral breast at the time of primary diagnosis is essential to reduce both time and cost to the patient.  Traditionally, breast MRI has been used to evaluate the breast for both ipsilateral (originally diagnosed) and contralateral disease; however, Positron Emission Mammography (PEM) is a 3-D molecular breast imaging approach that has been found to be as sensitive as breast MRI in detecting index and additional cancer in the ipsilateral breast with improved specificity.  

The study was conducted to determine whether PEM imaging would also be equally, or possibly more, sensitive than breast MRI for the identification of synchronous contralateral breast cancer. Of the 208 analyzable subjects, results showed that 71 women had contralateral breast lesions identified by either MRI or PEM.  The study confirmed that PEM and MRI identified the same cancers, both with 83% sensitivity, whereas PEM showed a trend for improved specificity with 80% vs. 63% with MRI.  PEM, unlike MRI, was not influenced by menopausal status or breast density.

"These results demonstrate that PEM has the potential to make significant contributions in pre-operative imaging evaluation of the contralateral breast in subjects with newly identified breast cancer," stated Dr. Kathy Schilling, Medical Director of Breast Imaging and Intervention for the Christine E. Lynn Women's Health and Wellness Institute at Boca Raton Regional Hospital.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan
2. Chemistry Researchers Create New Tool to Visualize Bloodstains
3. UPDATED: Elsevier Online Opinion Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
4. CulGenex™ by Hardy Diagnostics Assists Medical Researchers!
5. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
6. Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors
7. Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer
8. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
9. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
10. SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
11. Researchers Pave Way for Tracking of Prostate Motion With a Single kV Imager During Arc Radiotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... Fla. , Feb. 19, 2017  nThrive™, ... revenue cycle portfolio and thought leadership at the ... receiving a category leader award from KLAS. ... panel discussion focused on how market trends shape ... -  particularly a sophisticated, comprehensive Patient Access solution. ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue ... the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):